Yi Fang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4094200/publications.pdf

Version: 2024-02-01

1039880 996849 32 278 9 15 citations h-index g-index papers 33 33 33 352 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis. European Journal of Pharmacology, 2020, 884, 173444.	1.7	36
2	Probiotics for the treatment of women with bacterial vaginosis: A systematic review and meta-analysis of randomized clinical trials. European Journal of Pharmacology, 2019, 864, 172660.	1.7	33
3	The effect of genistein on glucose control and insulin sensitivity in postmenopausal women: A meta-analysis. Maturitas, 2017, 97, 44-52.	1.0	31
4	Protective effect of rhGLP-1 (7–36) on brain ischemia/reperfusion damage in diabetic rats. Brain Research, 2015, 1602, 153-159.	1.1	23
5	Identification of Components in Citri Sarcodactylis Fructus from Different Origins via UPLC-Q-Exactive Orbitrap/MS. ACS Omega, 2021, 6, 17045-17057.	1.6	22
6	Neuroprotection of rhGLPâ€l in diabetic rats with cerebral ischemia/reperfusion injury via regulation of oxidative stress, EAAT2, and apoptosis. Drug Development Research, 2018, 79, 249-259.	1.4	17
7	Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis. Diabetes Research and Clinical Practice, 2021, 177, 108904.	1.1	17
8	A Systematic Review and Meta-Analysis: Safety and Efficacy of Mesenchymal Stem Cells Therapy for Heart Failure. Current Stem Cell Research and Therapy, 2021, 16, 354-365.	0.6	14
9	Neuroprotective Effects of rhGLPâ€1 in Diabetic Rats with Cerebral Ischemia/Reperfusion Injury. Drug Development Research, 2016, 77, 124-133.	1.4	12
10	RhGLP-1 (7–36) protects diabetic rats against cerebral ischemia-reperfusion injury via up-regulating expression of Nrf2/HO-1 and increasing the activities of SOD. Korean Journal of Physiology and Pharmacology, 2017, 21, 475.	0.6	10
11	Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis. Acta Pharmacologica Sinica, 2010, 31, 1500-1507.	2.8	8
12	A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. Expert Opinion on Investigational Drugs, 2020, 29, 755-762.	1.9	8
13	Pharmacokinetic Properties and Safety Profile of Histamine Dihydrochloride Injection in Chinese Healthy Volunteers: A Phase I, Single-center, Open-label, Randomized Study. Clinical Therapeutics, 2015, 37, 2352-2364.	1.1	6
14	The long-term efficacy of cytokine-induced killer cellular therapy for hepatocellular carcinoma: a meta-analysis. Immunotherapy, 2019, 11, 1325-1335.	1.0	6
15	Risk of Dyslipidemia Associated with VEGF/VEGFR Inhibitors: A Meta-Analysis. Translational Oncology, 2020, 13, 100779.	1.7	6
16	Development and validation of a rapid and sensitive liquid chromatography–tandem mass spectrometry method for benvitimod quantification in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 885-886, 160-165.	1.2	4
17	An optimized HPLC/MS/MS method for quantification of excitatory amino acids in rat hippocampus and its application in brain ischemia/reperfusion research. Biomedical Chromatography, 2014, 28, 1822-1827.	0.8	4
18	A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects. BioDrugs, 2019, 33, 93-100.	2.2	4

#	Article	IF	Citations
19	A randomized controlled dose-escalation study of SSS07, a humanized rabbit anti-human TNF alpha antibody, in healthy Chinese adults. International Immunopharmacology, 2019, 75, 105807.	1.7	3
20	Randomised, double-blind, multicentre, phase $\hat{a}/\hat{a}i$ dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol. BMJ Open, 2020, 10, e039067.	0.8	3
21	Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus. Clinical Drug Investigation, 2017, 37, 1107-1115.	1.1	2
22	Pharmacokinetics and immunogenicity of T0001, a newly developed anti-TNF \hat{l}_{\pm} fusion protein, in healthy volunteers. European Journal of Clinical Pharmacology, 2017, 73, 1095-1101.	0.8	2
23	Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial. Expert Opinion on Biological Therapy, 2022, 22, 253-262.	1.4	2
24	Single Arm, Multi-Center, Phase II Study Of Clofarabine In Chinese Pediatric Patients With Refractory Or Relapsed Acute Lymphoblastic Leukemia. Blood, 2013, 122, 5016-5016.	0.6	2
25	Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 1004, 37-45.	1.2	1
26	A Randomized Study on the Bioequivalence of Desloratadine in Healthy Chinese Subjects and the Association of Different Metabolic Phenotypes With UGT2B10 and CYP2C8 Genotypes. Current Drug Metabolism, 2020, 21, 1031-1039.	0.7	1
27	Randomised, double-blind, multicentre, phase â/â; dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol. BMJ Open, 2020, 10, e039067.	0.8	1
28	rHuPH20-facilitated subcutaneous administration of monoclonal antibodies in cancer therapy. Immunotherapy, 2021, 13, 79-88.	1.0	0
29	Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial. International Immunopharmacology, 2021, 91, 107263.	1.7	0
30	Safety and tolerability of a single dose T0001 in Chinese healthy adult volunteers: a first-in-human ascending dose study. Brazilian Journal of Pharmaceutical Sciences, 0, 56, .	1.2	0
31	A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis. Clinical Therapeutics, 2021, 43, 2013-2023.	1.1	0
32	Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease. Drugs in R and D, 2022, , 1.	1.1	O